Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients (ISS OBS T-004)
Recruitment status was Recruiting
Tat is a key HIV regulatory protein produced very early after infection, prior to virus integration, and necessary for viral gene expression, cell-to-cell virus transmission and disease progression. Previous studies in natural HIV infection, indicated that the presence of a Tat-specific immune response correlates with a lower incidence and reduced risk of progression to AIDS as compared to anti-Tat negative individuals suggesting that an immune response to Tat may exert a protective role and control the progression to AIDS in vivo.
On the basis of the above mentioned consideration, the present study is directed at investigating the seroprevalence of anti-Tat antibodies in HIV-infected South African patients.
|Study Design:||Time Perspective: Cross-Sectional|
|Official Title:||A Multicentre, Observational, Cross-sectional Study to Assess the Seroprevalence of Anti-Tat Antibodies in HIV-infected Patients in Selected Areas of Gauteng and Eastern Cape|
- Anti-Tat Antibody Responses [ Time Frame: Up to 14 months ] [ Designated as safety issue: No ]Assessment of serum anti-Tat antibodies. Anti-Tat humoral immune response will include the determination of serum IgM, IgG and IgA antibodies against both clade B- and C-derived Tat proteins and titration of IgM, IgG and IgA anti-Tat antibodies.
- Virological status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ] [ Designated as safety issue: No ]
HIV viral load and clinical status on anti-Tat+ versus anti-Tat- participants. The effect of ARV treatment non-compliance on viral load in anti-Tat+ versus anti-Tat- participants will be evaluated within the ARV-treated study group on the basis of the relevant available information.
Hepatitis B, Syphilis, HPV co-infections Assessment.
- Immunological status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ] [ Designated as safety issue: No ]Assessment of CD4 T cell counts. Exploratory immunological assays may be performed on available residual samples for a more in-depth characterisation of the immune response.
- Immune activation status of anti-Tat positive and negative participants [ Time Frame: Up to 14 months ] [ Designated as safety issue: No ]Assessment of Immune-activation markers on CD4+ and CD8+ T cells (CD25+, CD38+ and HLA-DR+).
Biospecimen Retention: Samples With DNA
Whole blood, cervical samples
|Study Start Date:||October 2010|
|Treatment-naive HIV+ subjects|
|HAART-treated HIV+ subjects|
This is an observational, cross-sectional study aimed at assessing the frequency, magnitude and quality of the anti-Tat antibody response in both antiretroviral (ARV)-treated and treatment-naïve HIV-infected South African adults, and at exploring the correlation between the presence of anti-Tat antibody response and the immunological status of participants as well as with the presence of co-infections such as HBV, syphilis and HPV (the latter only for female participants).
The study will involve 700 participants and will provide important information for the planning, design and conduction of future therapeutic clinical trials with the Tat-based HIV vaccine in South African individuals.
This study is conducted in the frame of the Government-to-Government cooperation program N. AID 8421, funded by the Italian Ministry of Foreign Affairs-Directorate General for Development Cooperation (MAE-DGCS) and jointly implemented by the Italian Istituto Superiore di Sanita' (ISS) and the South African Department of Health in collaboration with the South African AIDS Vaccine Initiative of the Medical Research Council (MRC-SAAVI)
|Walter Sisulu University HIV Vaccine Research Unit||Not yet recruiting|
|Mthatha, Eastern Cape, South Africa|
|Contact: Jimmy Chandia, MD +27 047 502 ext 2111 firstname.lastname@example.org|
|Principal Investigator: Jimmy Chandia, MD|
|Medunsa Clinical Reasearch Unit||Recruiting|
|Medunsa, Gauteng, South Africa|
|Contact: Maphoshane Nchabeleng, MD +27 012 521 ext 5667 Maphoshane.Nchabeleng@ul.ac.za|
|Principal Investigator: Maphoshane Nchabeleng, MD|
|Study Director:||Barbara BE Ensoli, MD PhD||Istituto Superiore di Sanita|